1122089-67-1

Basic information

• Product Name: 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid
• Synonyms: 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid
• CAS NO: 1122089-67-1
• Molecular Weight: 221.256
• Mol File: 1122089-67-1.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid(1122089-67-1)
• EPA Substance Registry System: 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid(1122089-67-1)

Safety Data

• Hazardous Substances Data: 1122089-67-1(Hazardous Substances Data)

Usage

General Description

2-cyclopentyl-6-methoxypyridine-4-carboxylic acid is a chemical compound with the molecular formula C14H17NO3. It is a derivative of pyridine and contains a carboxylic acid group, a methoxy group, and a cyclopentyl group. 2-cyclopentyl-6-methoxypyridine-4-carboxylic acid is used in pharmacological research and drug development as it exhibits potential therapeutic effects in the treatment of various medical conditions. Studies have shown that this compound may have anti-inflammatory, analgesic, and neuroprotective properties. Further research is being conducted to explore its potential use in the treatment of neurological disorders and inflammatory conditions.

Upstream product

• 42521-09-5 methyl 2,6-dichloroisonicotinate 
• 1368348-22-4 2-cyclopentyl-6-hydroxyisonicotinic acid 
• 865-33-8 potassium methanolate 
• 77-78-1 dimethyl sulfate 
• 138837-21-5 tert-butyl 1-acetylcyclopentanecarboxylate 
• 6004-60-0 1-cyclopentylethanone 
• 28247-15-6 ethyl 1-acetylcyclopropane-1-carboxylate 
• 1033443-97-8 ethyl 4-cyclopentyl-2,4-dioxobutanoate 
• 67-56-1 methanol 
• 1262413-92-2 2-cyclopentyl-6-methoxyisonicotinic acid methyl ester 
• 42521-10-8 2-chloro-6-methoxyisonicotinic acid methyl ester 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 15855-06-8 2-chloro-6-methoxy-isonicotinic acid 

Downstream Products

• 1262414-06-1 4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenol 
• 1262414-05-0 (R)-3-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}propane-1,2-diol 
• 1391464-10-0 3-(2-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}ethylamino)propionic acid 
• 1391465-35-2 2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethanol 
• 1391465-37-4 2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl methanesulfonate 
• 1391465-38-5 ethyl 3-((2-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)ethyl)amino)propanoate 
• 1391465-39-6 (S)-5-(2-cyclopentyl-6-methoxypyridin-4-yl)-3-(3-ethyl-5-methyl-4-(oxiran-2-ylmethoxy)phenyl)-1,2,4-oxadiazole 
• 1391464-17-7 {4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}acetic acid 
• 1391465-41-0 (S)-2-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)acetic acid ethyl ester 
• 1391464-24-6 ((S)-3-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-2-hydroxypropylamino)acetic acid 
• 1391464-32-6 2-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-N-(2-hydroxyethyl)acetamide 
• 1391465-43-2 (S)-1-amino-3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propan-2-ol 
• 1391465-46-5 (S)-ethyl 3-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)-3-oxopropanoate 
• 1391464-33-7 (S)-3-((3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)amino)-3-oxopropanoic acid 

Relevant articles and documents

S1P1 AGONIST AND APPLICATION THEREOF

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.

Synthetic method of novel feed additive

The invention discloses a synthetic method of a novel feed additive and belongs to the technical field of synthesis of feed additives. The novel feed additive has the structure shown in the specification, wherein R1 is an oxygen atom or a nitrogen atom, R2 is cyclopentane, cyclobutane or cyclopropane, and R3 is methyl, ethyl or phenyl. The invention further discloses a preparation method of the novel feed additive. The novel feed additive is synthesized with the novel method, operation is simple and easy to perform in the reaction process, raw materials are low in price and easy to obtain, the reaction efficiency is relatively high, the repetition is relatively good, and the novel feed additive has a good growth promoting function on grow-finishing pigs.

Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines

In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P1 receptor agonist. More detailed studies revealed that this compound is phototoxic in vitro. As a result of efforts aiming at eliminating this undesired property, a series of alkoxy substituted pyridine derivatives was discovered. The photo irritancy factor (PIF) of these alkoxy pyridines was significantly lower than the one of aminopyridine 1 and most compounds were not phototoxic. Focused SAR studies showed, that 2-, 3-, and 4-pyridine derivatives delivered highly potent S1P1 receptor agonists. While the 2-pyridines were clearly more selective against S1PR3, the corresponding 3- or 4-pyridine analogues showed significantly longer oral half-lives and as a consequence longer pharmacological duration of action after oral administration. One of the best compounds, cyclopentoxy-pyridine 45b lacked phototoxicity, showed EC50 values of 0.7 and 140 nM on S1PR1 and S1PR3, respectively, and maximally reduced the blood lymphocyte count for at least 24 h after oral administration of 10 mg/kg to Wistar rats.